Immunotherapies and molecularly targeted personalized medicine have recently advanced the field of oncology in many cancer types; however, targeted agents against recurrent EGFR mutations and immune checkpoint inhibitors have so far not improved overall survival for GBM patients (13–19). This evidence concerns the gene EGFR and glioblastoma.